The virtual heart as a platform for screening drug cardiotoxicity

British Journal of Pharmacology

Volumn 172, Issue 23, 2015, Pages 5531-5547

  Yuan, Yongfeng ^a   Bai, Xiangyun ^a   Luo, Cunjin ^a   Wang, Kuanquan ^a   Zhang, Henggui ^a,b  

^a HARBIN INSTITUTE OF TECHNOLOGY   (China)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BIOLOGICAL MARKER; CALCIUM CHANNEL; CISAPRIDE; ION CHANNEL; POTASSIUM CHANNEL;

ALLOSTERISM; ARRHYTHMOGENESIS; BINDING AFFINITY; CARDIOTOXICITY; COMPUTER MODEL; COMPUTER SIMULATION; DRUG PROTEIN BINDING; DRUG SCREENING; ELECTRIC ACTIVITY; MATHEMATICAL MODEL; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; QUANTITATIVE ANALYSIS; REVIEW; VIRTUAL HEART; ANIMAL; DRUG EFFECTS; HEART; HUMAN; PRECLINICAL STUDY; PROCEDURES; TOXICITY TESTING;

ANIMALS; CARDIOTOXICITY; DRUG EVALUATION, PRECLINICAL; HEART; HUMANS; TOXICITY TESTS;

EID: 84949533120     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12996     Document Type: Review

References (100)

1. Adeniran I, McPate MJ, Witchel HJ, Hancox JC, Zhang H, (2011). Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndrome. PLoS Comput Biol 7: e1002313.
2. Aguilar-Shardonofsky M, Vigmond EJ, Nattel S, Comtois P, (2012). In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics. Biophys J 102: 951-960.
3. Ahrens-Nicklas RC, Clancy CE, Christini DJ, (2009). Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling. Cardiovasc Res 82: 439-447.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
6. Beeler GW, Reuter H, (1977). Reconstruction of the action potential of ventricular myocardial fibres. J Physiol 268: 177-210.
7. Bottino D, Penland RC, Stamps A, Traebert M, Dumotier B, Georgiva A, et al. (2006). Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Prog Biophys Mol Biol 90: 414-443.
8. Cardona K, Trenor B, Rajamani S, Romero L, Ferrero JM, Saiz J, (2010). Effects of late sodium current enhancement during LQT-related arrhythmias. A simulation study. Conf Proc IEEE Eng Med Biol Soc 2010: 3237-3240.
9. Cimponeriu A, Starmer CF, Bezerianos A, (2003). Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study. IEEE Trans Biomed Eng 50: 168-177.
10. Clancy CE, Rudy Y, (2002). Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation 105: 1208-1213.
11. Clancy CE, Zhu ZI, Rudy Y, (2007). Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol 292: H66-H75.
12. Clayton RH, Bernus O, Cherry EM, Dierckx H, Fenton FH, Mirabella L, et al. (2011). Models of cardiac tissue electrophysiology: progress, challenges and open questions. Prog Biophys Mol Biol 104: 22-48.
13. Colman MA, Varela M, Hancox JC, Zhang H, Aslanidi OV, (2014). Evolution and pharmacological modulation of the arrhythmogenic wave dynamics in canine pulmonary vein model. Europace 16: 416-423.
14. Comtois P, Sakabe M, Vigmond EJ, Munoz M, Texier A, Shiroshita-Takeshita A, et al. (2008). Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates. Am J Physiol Heart Circ Physiol 295: H1489-H1504.
15. Corrias A, Jie X, Romero L, Bishop MJ, Bernabeu M, Pueyo E, et al. (2010). Arrhythmic risk biomarkers for the assessment of drug cardiotoxicity: from experiments to computer simulations. Philos Trans A Math Phys Eng Sci 368: 3001-3025.
16. Courtemanche M, Ramirez RJ, Nattel S, (1998). Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am J Physiol 275 (1 Pt 2): H301-H321.
17. Di Diego JM, Belardinelli L, Antzelevitch C, (2003). Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 108: 1027-1033.
18. Di Veroli GY, Davies MR, Zhang H, Abi-Gerges N, Boyett MR, (2014). hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment. J Cardiovasc Electrophysiol 25: 197-207.
19. DiMasi JA, Hansen RW, Grabowski HG, (2003). The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185.
20. Dux-Santoy L, Sebastian R, Felix-Rodriguez J, Ferrero JM, Saiz J, (2011). Interaction of specialized cardiac conduction system with antiarrhythmic drugs: a simulation study. IEEE Trans Biomed Eng 58: 3475-3478.
21. Ebihara L, Johnson EA, (1980). Fast sodium current in cardiac muscle. A quantitative description. Biophys J 32: 779-790.
22. Faber GM, Rudy Y, (2007). Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism. Cardiovasc Res 75: 79-88.
23. Faber GM, Silva J, Livshitz L, Rudy Y, (2007). Kinetic properties of the cardiac L-type Ca2+ channel and its role in myocyte electrophysiology: a theoretical investigation. Biophys J 92: 1522-1543.
24. Fink M, Noble D, Virag L, Varro A, Giles WR, (2008). Contributions of HERG K+ current to repolarization of the human ventricular action potential. Prog Biophys Mol Biol 96: 357-376.
25. Fitzhugh R, (1961). Impulses and physiological states in theoretical models of nerve membrane. Biophys J 1: 445-466.
26. Fossa AA, Wisialowski T, Wolfgang E, Wang E, Avery M, Raunig DL, et al. (2004). Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. Eur J Pharmacol 486: 209-221.
27. Fredj S, Sampson KJ, Liu H, Kass RS, (2006). Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 148: 16-24.
28. Friedrichs GS, Patmore L, Bass A, (2005). Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. J Pharmacol Toxicol Methods 52: 6-11.
29. Gima K, Rudy Y, (2002). Ionic current basis of electrocardiographic waveforms: a model study. Circ Res 90: 889-896.
30. Gintant G, (2012). Ions, equations and electrons: the evolving role of computer simulations in cardiac electrophysiology safety evaluations. Br J Pharmacol 167: 929-931.
31. Henriquez CS, (2014). A brief history of tissue models for cardiac electrophysiology. IEEE Trans Biomed Eng 61: 1457-1465.
32. Hill AP, Perrin MJ, Heide J, Campbell TJ, Mann SA, Vandenberg JI, (2014). Kinetics of drug interaction with the Kv11.1 potassium channel. Mol Pharmacol 85: 769-776.
33. Hille B, (1977). Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 69: 497-515.
34. Hondeghem LM, Katzung BG, (1977). Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta 472: 373-398.
35. Hondeghem LM, Carlsson L, Duker G, (2001). Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004-2013.
36. Hondeghem LM, Dujardin K, Hoffmann P, Dumotier B, De Clerck F, (2011). Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. J Cardiovasc Pharmacol 57: 589-597.
37. Hund TJ, Rudy Y, (2004). Rate dependence and regulation of action potential and calcium transient in a canine cardiac ventricular cell model. Circulation 110: 3168-3174.
38. Iyer V, Mazhari R, Winslow RL, (2004). A computational model of the human left-ventricular epicardial myocyte. Biophys J 87: 1507-1525.
39. Kapela A, Tsoukias N, Bezerianos A, (2005). New aspects of vulnerability in heterogeneous models of ventricular wall and its modulation by loss of cardiac sodium channel function. Med Biol Eng Comput 43: 387-394.
40. Karagueuzian HS, Stepanyan H, Mandel WJ, (2013). Bifurcation theory and cardiac arrhythmias. Am J Cardiovasc Dis 3: 1-16.
41. Kenakin T, (2004). Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25: 186-192.
42. Kharche S, Yu J, Lei M, Zhang H, (2011). A mathematical model of action potentials of mouse sinoatrial node cells with molecular bases. Am J Physiol Heart Circ Physiol 301: H945-H963.
43. Kneller J, Kalifa J, Zou R, Zaitsev AV, Warren M, Berenfeld O, et al. (2005). Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model. Circ Res 96: e35-e47.
44. Kodama I, Kamiya K, Toyama J, (1999). Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 84 (9A): 20R-28R.
45. Kohl P, Noble D, (2009). Systems biology and the virtual physiological human. Mol Syst Biol 5: 292.
46. Luo CH, Rudy Y, (1994a). A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ Res 74: 1071-1096.
47. Luo CH, Rudy Y, (1994b). A dynamic model of the cardiac ventricular action potential. II. After depolarizations, triggered activity, and potentiation. Circ Res 74: 1097-1113.
48. Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA, (2004). The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 43: 369-379.
49. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, et al. (2011). Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res 91: 53-61.
50. Mirams GR, Davies MR, Cui Y, Kohl P, Noble D, (2012). Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing. Br J Pharmacol 167: 932-945.
51. Moreno JD, Zhu ZI, Yang PC, Bankston JR, Jeng MT, Kang C, et al. (2011). A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms. Sci Transl Med 3: 98ra83.
52. Moreno JD, Yang PC, Bankston JR, Grandi E, Bers DM, Kass RS, et al. (2013). Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening. Circ Res 113: e50-e61.
53. Nakagawa H, Honjo H, Ishiguro YS, Yamazaki M, Okuno Y, Harada M, et al. (2010). Acute amiodarone promotes drift and early termination of spiral wave re-entry. Heart Vessels 25: 338-347.
54. Nekouzadeh A, Rudy Y, (2011). Continuum molecular simulation of large conformational changes during ion-channel gating. PLoS ONE 6: e20186.
55. Nishimura M, Follmer CH, Singer DH, (1989). Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther 251: 650-659.
56. Noble D, (1960). Cardiac action and pacemaker potentials based on the Hodgkin-Huxley equations. Nature 188: 495-497.
57. Noble D, (1962). A modification of the Hodgkin-Huxley equations applicable to Purkinje fibre action and pace-maker potentials. J Physiol 160: 317-352.
58. O'Hara T, Virag L, Varro A, Rudy Y, (2011). Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol 7: e1002061.
59. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-D1106.
60. Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin JP, (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159: 12-21.
61. Qu Z, Weiss JN, (2005). Effects of Na(+) and K(+) channel blockade on vulnerability to and termination of fibrillation in simulated normal cardiac tissue. Am J Physiol Heart Circ Physiol 289: H1692-H1701.
62. Ramirez RJ, Nattel S, Courtemanche M, (2000). Mathematical analysis of canine atrial action potentials: rate, regional factors, and electrical remodeling. Am J Physiol Heart Circ Physiol 279: H1767-H1785.
63. Romero L, Trenor B, Yang PC, Saiz J, Clancy CE, (2014). In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome. J Mol Cell Cardiol 72: 126-137.
64. Rudy Y, Silva JR, (2006). Computational biology in the study of cardiac ion channels and cell electrophysiology. Q Rev Biophys 39: 57-116.
65. Saiz J, Gomis-Tena J, Monserrat M, Ferrero JM Jr, Cardona K, Chorro J, (2011). Effects of the antiarrhythmic drug dofetilide on transmural dispersion of repolarization in ventriculum. A computer modeling study. IEEE Trans Biomed Eng 58: 43-53.
66. Sale H, Wang J, O'Hara TJ, Tester DJ, Phartiyal P, He JQ, et al. (2008). Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with long-QT syndrome. Circ Res 103: e81-e95.
67. Sanguinetti MC, Tristani-Firouzi M, (2006). hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
68. Sanguinetti MC, Jiang C, Curran ME, Keating MT, (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81: 299-307.
69. Shannon TR, Wang F, Puglisi J, Weber C, Bers DM, (2004). A mathematical treatment of integrated Ca dynamics within the ventricular myocyte. Biophys J 87: 3351-3371.
70. Silva J, Rudy Y, (2005). Subunit interaction determines IKs participation in cardiac repolarization and repolarization reserve. Circulation 112: 1384-1391.
71. Silva JR, Rudy Y, (2010). Multi-scale electrophysiology modeling: from atom to organ. J Gen Physiol 135: 575-581.
72. Silva JR, Pan H, Wu D, Nekouzadeh A, Decker KF, Cui J, et al. (2009). A multiscale model linking ion-channel molecular dynamics and electrostatics to the cardiac action potential. PNAS 106: 11102-11106.
73. Smith PL, Baukrowitz T, Yellen G, (1996). The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379: 833-836.
74. Starmer CF, (1987). Theoretical characterization of ion channel blockade. Competitive binding to periodically accessible receptors. Biophys J 52: 405-412.
75. Starmer CF, Grant AO, (1985). Phasic ion channel blockade. A kinetic model and parameter estimation procedure. Mol Pharmacol 28: 348-356.
76. Starmer CF, Grant AO, Strauss HC, (1984). Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics. Biophys J 46: 15-27.
77. Starmer CF, Packer DL, Grant AO, (1987). Ligand binding to transiently accessible sites: mechanisms for varying apparent binding rates. J Theor Biol 124: 335-341.
78. Starmer CF, Lastra AA, Nesterenko VV, Grant AO, (1991a). Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments. Circulation 84: 1364-1377.
79. Starmer CF, Nesterenko VV, Undrovinas AI, Grant AO, Rosenshtraukh LV, (1991b). Lidocaine blockade of continuously and transiently accessible sites in cardiac sodium channels. J Mol Cell Cardiol 23 (Suppl. 1): 73-83.
80. Starmer CF, Reddy MR, Namasivayam A, Singh M, (1994). Potassium channel blockade amplifies cardiac instability numerical studies of torsades de pointes. Indian J Physiol Pharmacol 38: 259-266.
81. Starmer CF, Romashko DN, Reddy RS, Zilberter YI, Starobin J, Grant AO, et al. (1995). Proarrhythmic response to potassium channel blockade. Numerical studies of polymorphic tachyarrhythmias. Circulation 92: 595-605.
82. Starmer CF, Colatsky TJ, Grant AO, (2003a). What happens when cardiac Na channels lose their function? 1. Numerical studies of the vulnerable period in tissue expressing mutant channels. Cardiovasc Res 57: 82-91.
83. Starmer CF, Grant AO, Colatsky TJ, (2003b). What happens when cardiac Na channel function is compromised? 2. Numerical studies of the vulnerable period in tissue altered by drugs. Cardiovasc Res 57: 1062-1071.
84. Starobin JM, Zilberter YI, Rusnak EM, Starmer CF, (1996). Wavelet formation in excitable cardiac tissue: the role of wavefront-obstacle interactions in initiating high-frequency fibrillatory-like arrhythmias. Biophys J 70: 581-594.
85. Terrenoire C, Clancy CE, Cormier JW, Sampson KJ, Kass RS, (2005). Autonomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation. Circ Res 96: e25-e34.
86. Trenor B, Ferrero JM Jr, Rodriguez B, Montilla F, (2005). Effects of pinacidil on reentrant arrhythmias generated during acute regional ischemia: a simulation study. Ann Biomed Eng 33: 897-906.
87. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA, (1995). HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269: 92-95.
88. Tsujimae K, Suzuki S, Murakami S, Kurachi Y, (2007). Frequency-dependent effects of various IKr blockers on cardiac action potential duration in a human atrial model. Am J Physiol Heart Circ Physiol 293: H660-H669.
89. ten Tusscher KH, Panfilov AV, (2006a). Alternans and spiral breakup in a human ventricular tissue model. Am J Physiol Heart Circ Physiol 291: H1088-H1100.
90. ten Tusscher KH, Panfilov AV, (2006b). Cell model for efficient simulation of wave propagation in human ventricular tissue under normal and pathological conditions. Phys Med Biol 51: 6141-6156.
91. ten Tusscher KH, Noble D, Noble PJ, Panfilov AV, (2004). A model for human ventricular tissue. Am J Physiol Heart Circ Physiol 286: H1573-H1589.
92. Varro A, Virag L, Papp JG, (1996). Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Br J Pharmacol 117: 1181-1186.
93. Villoutreix BO, Bastard K, Sperandio O, Fahraeus R, Poyet JL, Calvo F, et al. (2008). In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. Curr Pharm Biotechnol 9: 103-122.
94. Wilhelms M, Rombach C, Scholz EP, Dossel O, Seemann G, (2012). Impact of amiodarone and cisapride on simulated human ventricular electrophysiology and electrocardiograms. Europace 14 (Suppl. 5): v90-v96.
95. Wu L, Rajamani S, Shryock JC, Li H, Ruskin J, Antzelevitch C, et al. (2008). Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res 77: 481-488.
96. Wu L, Ma J, Li H, Wang C, Grandi E, Zhang P, et al. (2011). Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation 123: 1713-1720.
97. Xie X, Zou J, Wang QY, Noble CG, Lescar J, Shi PY, (2014). Generation and characterization of mouse monoclonal antibodies against NS4B protein of dengue virus. Virology 450-451: 250-257.
98. Zhang H, Hancox JC, (2004). In silico study of action potential and QT interval shortening due to loss of inactivation of the cardiac rapid delayed rectifier potassium current. Biochem Biophys Res Commun 322: 693-699.
99. Zhang H, Kharche S, Holden AV, Hancox JC, (2008). Repolarisation and vulnerability to re-entry in the human heart with short QT syndrome arising from KCNQ1 mutation-a simulation study. Prog Biophys Mol Biol 96: 112-131.
100. Zhou Q, Bett GC, Rasmusson RL, (2012). Markov models of use-dependence and reverse use-dependence during the mouse cardiac action potential. PLoS ONE 7: e42295.